Zacks Research Brokers Decrease Earnings Estimates for BAX

Baxter International Inc. (NYSE:BAX) – Stock analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Baxter International in a research note issued to investors on Wednesday, January 21st. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.59 per share for the quarter, down from their prior forecast of $0.60. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s FY2026 earnings at $2.17 EPS and Q4 2027 earnings at $0.62 EPS.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.09. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The company had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same period in the previous year, the business earned $0.80 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS.

Other analysts have also issued research reports about the company. Argus lowered Baxter International from a “buy” rating to a “hold” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. lowered their price objective on shares of Baxter International from $25.00 to $19.00 in a report on Friday, October 31st. The Goldman Sachs Group increased their target price on shares of Baxter International from $22.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, January 9th. Evercore ISI decreased their target price on shares of Baxter International from $24.00 to $23.00 in a research report on Monday, January 5th. Finally, Wells Fargo & Company cut their price target on shares of Baxter International from $21.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $21.40.

Baxter International Price Performance

BAX opened at $19.71 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.18 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $10.13 billion, a P/E ratio of -29.87, a PEG ratio of 1.13 and a beta of 0.59. The stock has a 50-day moving average price of $19.12 and a 200-day moving average price of $22.19. Baxter International has a 12-month low of $17.40 and a 12-month high of $37.74.

Institutional Trading of Baxter International

Several large investors have recently modified their holdings of the business. CoreFirst Bank & Trust purchased a new position in Baxter International during the 2nd quarter valued at about $27,000. Imprint Wealth LLC bought a new stake in shares of Baxter International in the 3rd quarter worth approximately $27,000. Creative Financial Designs Inc. ADV increased its stake in shares of Baxter International by 169.6% during the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 619 shares during the period. MTM Investment Management LLC bought a new position in shares of Baxter International during the second quarter valued at approximately $30,000. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Baxter International during the second quarter valued at approximately $40,000. 90.19% of the stock is owned by institutional investors.

Baxter International Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Friday, November 28th were given a $0.01 dividend. The ex-dividend date was Friday, November 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s payout ratio is presently -6.06%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.